Key data
| Regulation | Correction to Commission Implementing Regulation (EU) 2024/1381 of 23 May 2024 |
|---|---|
| Publication | 16 November 2026 |
| Entry into force | Not specified in the correction |
| Base regulation | Regulation (EU) 2021/2282 on health technology assessment (HTA) |
| Affected parties | Pharmaceutical industry, national health authorities and EU health technology assessment bodies |
| Category | European Regulation |
| Scope of mandatory application from | January 2025 (oncology medicines and advanced therapies) |
Pharmaceutical companies operating in the European Union have a new task ahead: reviewing their joint clinical evaluation files in light of the correction published on 16 November 2026 on the Commission Implementing Regulation (EU) 2024/1381. This correction rectifies material errors in the models and procedures for information exchange between industry, national authorities and the European Commission within the framework of the health technology assessment (HTA) system.
This is not a minor change in form. The corrected forms are what determine how clinical evidence is structured and presented to the evaluating authorities. Presenting data in obsolete or incorrect formats can translate directly into delays in evaluation and, therefore, in access to the European market.
What does this regulation establish?
The Regulation (EU) 2021/2282 on health technology assessment created a European framework for joint clinical evaluation of medicines. Its objective is for Member States to collaborate in the evaluation of the clinical evidence of medicines, rather than each country doing so independently and duplicated.
The Commission Implementing Regulation (EU) 2024/1381, adopted on 23 May 2024, established the specific procedures for that system: how the different actors interact, what information is exchanged, in what formats and with what documentation models. The correction now published rectifies material errors detected in those models and information exchange procedures.
| Corrected element | Description |
|---|---|
| Joint clinical evaluation models | Rectification of material errors in the forms that industry must complete |
| Information exchange procedures | Correction of processes between national authorities and the European Commission |
| Corrected regulation | Commission Implementing Regulation (EU) 2024/1381, originally published on 24 May 2024 (OJ L 2024/1381) |
The scope of application of the HTA system is progressive. Since January 2025, joint clinical evaluation is mandatory for oncology medicines and advanced therapies. The expansion to other categories of medicines will take place in a staggered manner in the following years.
Economic and operational impact
The impact of this correction is not of a direct sanctioning type, but it does have real economic consequences for pharmaceutical companies:
- Delays in joint evaluations: Submitting files with the previous (incorrect) models can cause the evaluation not to be accepted or to have to be repeated, delaying access to the European market.
- Cost of internal review: Regulatory Affairs departments will have to audit files in preparation and those already submitted to verify their compliance with the corrected forms.
- Impact on the approval chain: In oncology medicines and advanced therapies, where joint evaluation is already mandatory since January 2025, any delay has a direct impact on commercialization and projected revenues.
- Coordination with national authorities: Companies must ensure that their counterparts in each Member State also work with the corrected models, as the system involves information exchange between multiple actors.
Who does it affect?
- Pharmaceutical laboratories that market or plan to market medicines in the EU, especially in oncology and advanced therapies.
- Regulatory Affairs departments responsible for preparing and managing joint clinical evaluation files.
- National health authorities of Member States that participate in the joint evaluation process.
- National health technology assessment bodies (HTA bodies) that use the models and procedures established in Regulation 2024/1381.
- Consulting firms and CROs (Contract Research Organizations) that advise industry on the preparation of HTA files for the European market.
Practical example
A Spanish pharmaceutical company is preparing the joint clinical evaluation file for a new oncology medicine that it plans to launch in several European markets in 2026. Its Regulatory Affairs team has been working with the models of Commission Implementing Regulation (EU) 2024/1381 published in May 2024.
Following the publication of this correction on 16 November 2026, the company must:
- Identify which forms and models have been rectified by the correction.
- Compare the models it was using with the corrected models to detect discrepancies.
- Update all file documents that use the affected models.
- Verify with the national authorities of each Member State involved that they also work with the corrected version.
If the company does not carry out this review and submits the file with the previous models, it risks the joint evaluation being rejected or returned for correction, potentially delaying the process of access to the European market by several months.
What should companies do now?
- Access the official correction published on 16 November 2026 in the Official Journal of the EU (reference OJ:L_202690979) and identify exactly which models and procedures have been rectified.
- Audit files in preparation: Review all joint clinical evaluation documents that are in the development phase to verify if they use the models affected by the correction.
- Update internal forms: Replace the incorrect models with the corrected ones in all systems and internal templates of the Regulatory Affairs department.
- Communicate the change to partners and CROs: Inform all external providers participating in the preparation of HTA files about the need to use the corrected models.
- Confirm with national authorities: Contact the HTA bodies of the Member States where commercialization is planned to confirm that they work with the corrected version of the procedures.
- Document the adaptation: Record internally the actions taken to demonstrate compliance in case of audit or review by the authorities.
Frequently asked questions
Which medicines are already required to undergo European joint clinical evaluation?
Since January 2025, joint clinical evaluation is mandatory for oncology medicines and advanced therapies. The expansion to other categories of medicines will take place progressively in subsequent years, as established by Regulation (EU) 2021/2282.
What happens if I submit the HTA file with the models prior to the correction?
Submitting files with the incorrect models (prior to the correction of Regulation 2024/1381) can cause the joint evaluation not to be accepted or to have to be repeated. This translates into direct delays in the evaluation process and, therefore, in the access to the European market of the affected medicine.
When did the correction to Regulation 2024/1381 enter into force?
The correction was published on 16 November 2026. The specific date of entry into force is not indicated in the available information on the correction. It is recommended to consult the full text in the Official Journal of the EU (OJ:L_202690979) to verify the exact date of application.
Which national bodies does the change in information exchange procedures affect?
Changes in information exchange procedures affect the national health authorities and health technology assessment bodies (HTA bodies) of all EU Member States that participate in the joint clinical evaluation system regulated by Regulation (EU) 2021/2282.
Where can I consult the corrected models of Regulation 2024/1381?
The corrected models are available in the Official Journal of the European Union, in the correction published on 16 November 2026 with reference OJ:L_202690979. You can access it directly through EUR-Lex.
Official source
Consult complete regulation in official source
Disclaimer: This article is for informational purposes only and does not constitute legal advice. For specific decisions, consult a qualified professional. Source: https://eur-lex.europa.eu/./legal-content/AUTO/?uri=OJ:L_202690979